Quantcast

Latest DURECT Corporation Stories

2011-04-28 07:00:00

CUPERTINO, Calif., April 28, 2011 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2011 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2011-04-11 15:15:00

CUPERTINO, Calif., April 11, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR® (TRANSDUR®-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch.

2011-03-02 15:05:00

CUPERTINO, Calif., March 2, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2010.

2011-03-01 15:15:00

CUPERTINO, Calif., March 1, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 31st Annual Healthcare Conference on Monday, March 7 at 1:00 pm Eastern Time.

2011-02-07 16:30:00

CUPERTINO, Calif., Feb. 7, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 14 at 9:30 a.m. Eastern Time.

2011-01-27 07:45:00

CUPERTINO, Calif., Jan. 27, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for REMOXY® by King Pharmaceuticals, Inc.

2010-12-27 06:15:00

CUPERTINO, Calif., Dec. 27, 2010 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King has resubmitted a New Drug Application (NDA) for REMOXY® to the U.S.


Word of the Day
edulcoration
  • The act of sweetening by admixture of some saccharine substance.
The word 'edulcoration' comes from a Latin word meaning 'making sweet'.